"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

Moderately hypofractionated and conventionally fractionated radiotherapy demonstrate similar efficacy, but one ...

On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate ...

A new study has revealed that men who don't heed recommendations for prostate cancer screenings are at a significantly higher ...

Kidney stones and gallstones may increase the risk for prostate cancer, which could have implications for disease monitoring and prevention in specific populations. Patients with kidney stones or ...

Recovering erections grabs the attention of most men and their doctors after prostate cancer treatment. A new study redirects ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile ...

Physician-scored and patient-reported bowel toxicity higher with dose-escalated moderately hypofractionated radiotherapy.

Men who avoided prostate cancer screening appointments were significantly more likely to die from the disease, according to ...

The OPTIMUM study found 4.5% more clinically significant cancers among men who underwent micro-ultrasound–guided biopsies of ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...